RxDoctor Payments Data

Dara Santos, PA

Physician Assistant · Camp Hill, PANPI 1033405683

Payments from drug & device makers

$1,273in general payments, 2019–2025

Across 54 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$372
  • Regeneron Healthcare Solutions, Inc.$188
  • Amgen$125
  • E.r. Squibb & Sons, L.L.C.$125
  • Ardelyx, Inc.$104
  • Pfizer$82
  • plus $276 from 8 others

What the payments were for

  • Food & beverage$1,25799%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,273 in reported general payments places this provider in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$50,151
Medicare patients
303
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide88$82,879
Sucralfate87$12,133
Colesevelam Hcl45$8,605
Famotidine510$8,404
Dexlansoprazole DrDexlansoprazole31$6,809
Lubiprostone38$6,249
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates95$6,138
Omeprazole364$5,227
Pantoprazole Sodium263$3,679
Esomeprazole Magnesium79$2,564
Ursodiol12$2,464
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg73$1,901
Dicyclomine Hcl84$1,826
Balsalazide Disodium15$929
Ondansetron OdtOndansetron48$792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$372$82,87988 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →